Roivios, Ltd.

We’re thrilled to shine a spotlight on Alencia Washington, PhD, Vice President of Clinical Affairs at Roivios, for her incredible leadership and innovation in clinical research. This month, Dr. Washington is being honored in the Atlanta Business Chronicle’s Women’s History Month series, a testament to her exceptional contributions to #healthcare. Among her many achievements, she played a pivotal role in developing the?JuxtaFlow? Renal Assist Device (RAD), which proudly received?FDA Breakthrough Device Designation—a milestone in advancing patient care. The feature is live online now, with the print edition hitting newsstands on March 29! #KidneyHealth #LeadershipSpotlight #Roivios #WomensHistoryMonth?

March is #KidneyMonth, and we’re proud to raise awareness about kidney health while driving innovation in this vital field. Every day, kidneys filter 50 gallons of blood—an extraordinary task. For millions living with chronic kidney disease (CKD), this process begins to fail, impacting their health and straining healthcare systems worldwide. At Roivios, we’re addressing these challenges with solutions like the JuxtaFlow? Renal Assist Device (RAD)—designed to enhance kidney function and improve outcomes for patients. Want to learn more? Read our CEO John Erbey’s latest article for deeper insights into the urgency of rethinking kidney care and how #innovation can make a lasting difference. This Kidney Month, join us in creating a healthier future for kidney patients everywhere. #medicaldevice #healthtech #medtechinnovation

Sometimes a transformation opportunity is hiding in plain sight. History can often cloud our ability to see an "obvious" opportunity. One such obvious one to me that is hidden behind time is how we manage kidneys in the hospital. Our clinical teams are amazing. The innovation we have given them today was invented in the 1930s ( a gravity-fed foley), and a very difficult way to understand intra-abdominal pressure. By focusing on the context of care, my team and I were able to discover the friction and struggles of how kidneys are understood and managed today. Thank you to all of the doctors and nurses who do this sacred work. American College of Healthcare Executives National Kidney Foundation AACN (American Association of Critical-Care Nurses) Alice B. Kevin Lobdell Ashish K. Khanna MD,MS,FCCP,FCCM,FASA Tom Calabro WSACS - the Abdominal Compartment Society 120/80 MKTG, a 120/80 GROUP company Bob Moesta #transformation Scott Becker Carrie Arnold Accuryn Medical

This approach is deeply aligned with our mission at Roivios: taking bold steps to bridge past research with today’s advancements, bringing actionable solutions to light. We’d love to hear your thoughts! How do you see the evolution of research shaping the future of innovation??

Innovation at Roivios begins with bold ideas and visionary leadership—and Bryan J Tucker, Ph.D., our Senior Vice President of Applied Science, truly embodies this spirit. With over 30 years in medical devices and pharmaceuticals, Bryan has driven breakthroughs like the JuxtaFlow? Renal Assist Device (RAD) while leading NASA-backed research and training 700+ clinical investigators. His work transforms kidney disease management and improves patient outcomes. Beyond science, Bryan’s expertise shines as a certified wine judge, with a passion for fermentation and grape genealogy.?Whether developing life-changing technology or decoding the art of winemaking, Bryan brings the same meticulous attention to detail, creativity, and drive for excellence across everything he does. Thank you, Bryan, for leading the charge and inspiring us to think beyond limits. ???Discover more about Bryan's remarkable story here: #kidneyhealth #medicaldevices #protectthekidney #renalhealth #kidneydisease #roivios #ckd #kidneycare #inspiration

We’re excited to announce that John Erbey, CEO of Roivios, will be a featured panelist at LSI USA '25! ? Roivios has always been committed to pioneering innovative solutions that improve patient outcomes, and our partnership with?Caresyntax represents a bold step forward. Together, we’re redefining how Real World Evidence (RWE) can be harnessed to revolutionize healthcare and drive actionable insights across the entire ecosystem. ? Join us for the Fireside Chat titled?"Real World Evidence as Commercial Strategy for Startups and Strategics", where John Erbey will join industry leaders?Bruce Ramshaw, Chief Medical Informatics Officer at Caresyntax, and Liam J. Burns, CEO of Qaelon Medical, to explore how RWE is shaping innovation, optimizing clinical workflows, and transforming commercialization strategies. ? Why This Matters Our recent collaboration with Caresyntax has laid the groundwork for using surgical intelligence and real-world data to support breakthrough innovations like Roivios, Ltd.’s?JuxtaFlow? Renal Assist Device (RAD). Together, we’re creating a scalable approach to high-impact, evidence-based healthcare solutions that address critical challenges like renal care. ? Don’t Miss It This session is a must-attend for startups, strategics, and industry experts looking to understand the transformational potential of RWE. ? We’d love to hear your thoughts on the future of RWE in healthcare! Drop a comment below and feel free to share this post to amplify the conversation. ? #LSIUSA25 #RealWorldEvidence #HealthcareInnovation #Roivios #Caresyntax #QaelonMedical #ProtecttheKidney #KidneyDisease #KidneyHealth #RenalHealth #CKD

We’re excited to announce our partnership with Caresyntax, a leader in surgical intelligence, to redefine kidney care for high-risk patients. This collaboration integrates clinical and economic insights to enhance outcomes and reduce costs. ? At the core of this effort is the pivotal trial of our?JuxtaFlow? Renal Assist Device (RAD)—a groundbreaking technology designed to sustain kidney function during on-pump cardiac surgeries. With Caresyntax’s clinical data as a service (CDaaS) platform, we are capturing real-world evidence to measure and optimize JuxtaFlow RAD's value in real time. “Our partnership with Caresyntax exemplifies the future of medical device innovation,” says John Erbey, CEO of Roivios. “Real-time evidence empowers informed, patient-centered care while tackling critical unmet needs.” ? Together, we’re setting a new standard in renal care. ?Learn more: https://lnkd.in/eYZwzHYa cc: Bruce Ramshaw #healthcare #medicine #medicaldevices #healthcareinnovation #ProtecttheKidney #DigitalHealth #MedTech #KidneyHealth #KidneyDisease #Nephrology #CKD #ESRD

2024 has been a defining year for Roivios, Ltd. as we continue to push the boundaries of innovation in kidney care. Here are some milestones we’re proud to highlight: --> FDA Breakthrough Device Designation for JuxtaFlow RAD?— a recognition of its potential to protect kidney function during cardiac surgery and transform patient outcomes. > IDE Approval for the GRADIENT Trial?— an essential step in advancing research and improving care for patients with kidney dysfunction. --> Global Recognition?— from awards to collaborations, these accomplishments highlight the strength of our mission to revolutionize renal health. These achievements reflect our team's dedication to meaningful innovation and improving lives. Read more about our progress and what’s ahead in CEO John Erbey’s article https://lnkd.in/eutjNmjD

We’re excited to have our CEO, John Erbey, participate in the Bullpen during #JPM2025 on Monday, January 13, at the Golden Gate Yacht Club! Don’t miss the chance to connect with him to discuss how Roivios is driving the industry forward. ?? Email John for meetings:?[email protected] ?? Learn more at?roivios.com Shout out to Bullpen, our team, and our investors for making this possible. We’re bullish on the opportunities ahead—see you there! #KidneyHealth #ProtecttheKidney #RenalHealth #Roivios #MedTech #HealthcareInnovation #KidneyDisease #Healthcare #MedicalDevices #HealthcareLeadership

Proud Announcement from Roivios! We’re excited to share that the FDA has granted Investigational Device Exemption (IDE) approval for the pivotal trial of the JuxtaFlow? Renal Assist Device (RAD). This milestone brings us closer to transforming care for cardiac surgery patients with renal insufficiency, a population that faces significant post-surgery risks. JuxtaFlow RAD represents a decade of innovation and dedication, offering a novel approach to kidney support during times of acute stress. With this approval, we're set to launch the GRADIENT trial, designed to evaluate JuxtaFlow's potential to enhance renal function, reduce complications, and improve recovery for those undergoing cardiopulmonary bypass surgery. We’re eager to begin this next chapter and continue driving advancements in kidney health! Learn more about this exciting development in our press release?here: https://lnkd.in/eGpxAtsR #FDAApproval #JuxtaFlow #KidneyHealth #CardiacSurgery #Innovation #ProtecttheKidney #FDA #IDEApproval?